{"id":49279,"date":"2018-06-26T12:03:32","date_gmt":"2018-06-26T16:03:32","guid":{"rendered":"https:\/\/asweetlife.org\/?p=49279"},"modified":"2018-06-26T12:03:32","modified_gmt":"2018-06-26T16:03:32","slug":"jdrf-and-adas-wary-response-to-dr-faustmans-findings","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=49279","title":{"rendered":"JDRF and ADA’s Wary Response to Dr. Denise Faustman’s Findings"},"content":{"rendered":"
\n
\n

Today JDRF and the American Diabetes Association released a joint statement on the findings of Dr. Denise Faustman’s recently published study:<\/a><\/em><\/strong><\/p>\n

On June 25, Dr. Denise Faustman presented data at the ADA\u2019s 78th Scientific Sessions, and the information presented was published in a medical literature article in npj Vaccines<\/em>, a Nature Partner Journal. The findings in the June 21 article reported a follow-up study of people with established type 1 diabetes (T1D) treated with the bacillus Calmette-Gu\u00e9rin (BCG) vaccine, which evaluated the impact of the intervention and provided a hypothesis to support the notion that BCG vaccination could be beneficial for people with T1D.<\/p>\n

While this work has attracted attention, the study only followed a very small number of patients\u2014nine people at the five-year time point, and three people at the eight-year time point\u2014and must be interpreted with caution.<\/p>\n

Overall, the findings prompt thought-provoking questions but not definitive answers, and do not provide enough clinical evidence to support any recommended change in therapy at this time. Specific limitations that should be considered include:<\/p>\n